Although further validation is warranted, our results provide preliminary evidence implicating cholesterol biosynthesis as a mechanistic target in osteosarcoma and underscore the exploratory value of CaSR antagonists as metabolic regulators in cancer research. The gene discussed is CASR; the disease is cancer.